Evidence map›Paper›PMID 35279610›Full record

ArticleEuropean journal of medicinal chemistry2022

Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.

Xintong Zhang, Yulong Shi, Zhihao Guo, Xiaoqiang Zhao, Jiajing Wu, Shouchun Cao, Yonghua Liu, Yuhua Li, Weijin Huang, Youchun Wang and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Clofazimine for the treatment of tuberculosis.Frontiers in pharmacology · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xintong ZhangBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.
Yulong ShiBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.
Zhihao GuoBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.
Xiaoqiang ZhaoBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.
Jiajing WuNational Institutes for Food and Drug Control, Beijing, 100050, China.
Shouchun CaoNational Institutes for Food and Drug Control, Beijing, 100050, China.
Yonghua LiuBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China.
Yuhua LiNational Institutes for Food and Drug Control, Beijing, 100050, China.
Weijin HuangNational Institutes for Food and Drug Control, Beijing, 100050, China.
Youchun WangNational Institutes for Food and Drug Control, Beijing, 100050, China.
Qiang LiuNational Institutes for Food and Drug Control, Beijing, 100050, China.
Yinghong LiBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China. Electronic address: liyinghong@imb.pumc.edu.cn.
Danqing SongBeijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100050, China. Electronic address: songdanqing@imb.pumc.edu.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNational Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thirty-two clofazimine derivatives, of which twenty-two were new, were synthesized and evaluated for their antiviral effects against both rabies virus and pseudo-typed SARS-CoV-2, taking clofazimine (1) as the lead. Among them, compound 15f bearing 4-methoxy-2-pyridyl at the N5-position showed superior or comparable antiviral activities to lead 1, with the EC

Indexed as

Antiviral AgentsCOVID-19ClofazimineHumansSARS-CoV-2Antiviral AgentsClofazimineBroad-spectrumClofazimine analoguesRabies virusSARS-CoV-2Structure–activity relationship

Identifiers

PMID35279610
PMCPMC8897968
OpenAlexW4220784032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.